Allumiqs has entered into a long-term strategic collaboration with Prolytix to expedite the discovery and development of new drugs.
The alliance aims to deliver partnered and integrated offerings that enhance the efficiency of drug development pipelines, providing customers with advanced bioanalytical support.
Go deeper with GlobalData
Such solutions will facilitate in progressing drug candidates from the initial research and development (R&D) phases through to commercialisation.
Allumiqs serves as a contract research organisation (CRO) solutions partner for biotech and biopharma companies.
With its liquid chromatography with tandem mass spectrometry (LC-MS) and multiomics expertise, data analytics and insights, the CRO aids in saving the cost and time required for drug development.
See Also:
The company offers both on-demand and tailored solutions to support the progression of drug candidates.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe latest partnership builds on a history of successful joint customer engagements.
Allumiqs will provide its proficiency in multiomics and LC-MS solutions, while Prolytix will contribute its broad experience in large-molecule drug product life cycle management.
Together, they provide cohesive solutions that could streamline the drug development process.
Allumiqs plays a crucial role in the early R&D phases by offering biological insights and therapeutic characterisation, comprising mechanism of action, biomarker detection and drug product characteristics.
Once this is complete, customers move to Prolytix for targeted method development which encompasses stability, potency and good manufacturing practice release testing.
The partnership ensures the smooth transition of critical R&D work, minimising the complexities and risks associated with engaging separate vendors.
The combined expertise of Allumiqs and Prolytix will offer customers a unified team of specialists, streamlining the drug development process and reducing the time to market for new therapies.
Allumiqs CEO Kent MacLean stated: “We found many synergies in working with the team at Prolytix in collaborative customer projects, most importantly our shared commitment to customer success.
“Now, in partnership with Prolytix, we can take all of our customers further in the drug development process with connected solutions from early R&D to lot release. Our goal is to make it simple for our customers to engage with the innovation partners they need at every stage of the drug discovery process, and our partnership with Prolytix does that.”
